Martingale Asset Management L P Increases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Martingale Asset Management L P raised its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 7.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 58,650 shares of the biopharmaceutical company’s stock after acquiring an additional 4,200 shares during the period. Martingale Asset Management L P’s holdings in Theravance Biopharma were worth $552,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in Theravance Biopharma during the 4th quarter valued at $69,000. Teacher Retirement System of Texas bought a new stake in Theravance Biopharma in the 4th quarter worth $103,000. XTX Topco Ltd increased its position in shares of Theravance Biopharma by 34.5% in the third quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 5,243 shares during the period. SG Americas Securities LLC raised its stake in shares of Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,349 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Theravance Biopharma by 27.6% during the fourth quarter. Wells Fargo & Company MN now owns 21,704 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 4,695 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Trading Up 0.1 %

Shares of Theravance Biopharma stock opened at $8.40 on Friday. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $10.90. The company has a market cap of $415.56 million, a P/E ratio of -8.32 and a beta of 0.14. The company’s fifty day simple moving average is $9.18 and its two-hundred day simple moving average is $9.13.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million. Analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $11.33.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.